// App-Quantinova.ai

P1728 : THE FUTURE OF MYELODYSPLASTIC SYNDROME – PATIENT PRIORITIES AND OUTCOMES THAT MATTER

Researchers

Presenter

  • Matthew Poynton

Principal Investigators

  • Simon Stanworth

  • Michael Murphy

Medical Centers

  • NHS Blood and Transplant,Oxford,Verenigd Koninkrijk

  • Oxford University Hospitals NHS Trust, Oxford,

  • NHS Blood and Transplant, Oxford, United Kingdom

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • Oxford University Hospitals NHS Trust,Oxford,Vereinigtes Königreich

  • NHS Blood and Transplant,Oxford,Соединённое Королевство

  • NHS Blood and Transplant,Oxford,Royaume-uni

  • NHS Blood and Transplant,Oxford,Vereinigtes Königreich

  • NHS Blood and Transplant,Oxford,Reino Unido

  • NHS Blood and

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • Oxford University Hospitals NHS Trust, Oxford,

  • NHS Blood and Transplant,Oxford,Reino Unido

  • Oxford University Hospitals NHS Trust,Oxford,Verenigd Koninkrijk

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Alpha-thalassemia myelodysplasia syndrome

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved